Enterprise Value
7.766B
Cash
846.3M
Avg Qtr Burn
-91.76M
Short % of Float
7.68%
Insider Ownership
15.33%
Institutional Own.
85.23%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tavapadon (adjunct with L-Dopa) Details Parkinson's disease, Brain disease | Phase 3 Data readout | |
Tavapadon Details Parkinson's disease, Brain disease | Phase 3 Data readout | |
Phase 2 Data readout | ||
Darigabat Details Social Anxiety Disorder, Panic Disorder | Phase 2 Data readout | |
Phase 2 Data readout | ||
Darigabat (CVL-865) Details Epilepsy | Phase 2 Data readout | |
Emraclidine (CVL-231) Details Brain disease, Neurodegenerative disease, Alzheimer's disease | Phase 1 Data readout | |
CVL-354 Details Major depressive disorder | Phase 1 Data readout |